Exact Sciences presented data from a study on its blood-based colorectal cancer test at the European Society for Medical Oncology Congress. The test showed 88.3% sensitivity for detecting colorectal cancer and 31.2% for advanced precancerous lesions, with a specificity of 90.1%. This development brings the test closer to providing a non-invasive screening option. Analysts reacted positively but expressed concern over potential performance degradation, with final results from the BLUE-C study expected by the first half of 2025.
Keep Reading
Add A Comment